Pharmaceuticals

Neumora Therapeutics

Mizuho Reiterates Buy Rating on Neumora Therapeutics

Neumora Therapeutics released FY2025 Q3 earnings on November 6, 2025 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3506 (forecast USD -0.3333)

Neumora Therapeutics released FY2025 9 Months Earnings on November 6, 2025 (EST), with actual revenue of USD 0 and EPS of USD -1.0979

Neumora Announces Advances in Neuroscience Drug Development

ARCH Venture Partners X, LLC Acquires Common Shares of Neumora Therapeutics Inc.

Analyst Suneja Reiterates Buy Recommendation on Neumora Therapeutics

Suvannavejh and H.C. Wainwright Reaffirm Buy Rating and Price Target for Neumora Therapeutics Inc.

Neumora Therapeutics Launches Phase 1 Clinical Trial for NMRA-898

Suvannavejh Maintains Buy Rating on Neumora Therapeutics with Price Target of $18

Neumora Therapeutics Inc Holds Virtual R&D Day to Showcase Pipeline Progress

Neumora Therapeutics released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.33 (forecast USD -0.3697)

Neumora Therapeutics released FY2025 Semi-Annual earnings on August 6 After-Market EST, actual revenue USD 0, actual EPS USD -0.7471

Neumora Therapeutics to Release FY2025 Q2 Earnings on August 6 After-Market (EST), Forecast EPS -0.3697 USD

FactSet Analysts Give Neumora an Overweight Rating with a Price Target

Neumora Holds Annual General Meeting

Kuehn Law Investigating Possible Misstatements by Neumora Therapeutics

SoftBank Reduces Stake in Neumora Therapeutics

HC Wainwright Downgrades Neumora Therapeutics 2025 Q2 Earnings Forecast

Neumora Therapeutics reports Q1 2025 net loss of $68 million

Neumora Therapeutics released FY2025 Q1 earnings during market hours on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4211 (forecast USD -0.385)

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Tradr 2X Long ASTS Daily ETF

Able View Global

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap